Kristie L. Kahl

“You have to speak up. What you don’t say is the most predictive of the care you don’t get.”

Patients can pick from a growing array of treatments, from same-day- results surgery to game-changing immunotherapy, to fight the most common type of cancer.

In this episode of the “CURE Talks Cancer” podcast we spoke with two experts on the treatment landscape of metastatic urothelial carcinoma and what patients have to look forward to.

The Food and Drug Administration approved Bavencio as a first-line maintenance therapy for patients with locally advanced or metastatic urothelial carcinoma.

In this episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Jonathon Leventhal about skin cancer and what individuals should know about the disease.

Andrea Dwyer spoke with CURE® about the symposium and why it is important to raise global awareness around the increasing rate of early-age onset colorectal cancer.

The Food and Drug Administration approved the second biomarker-based indication for Keytruda to treat adult and pediatric patients with unresectable or metastatic TMB-H solid tumors across cancer types, including rare cancers.

The phase 3 PROTECTIVE-2 (Study 106) trial met its primary and secondary end points in preventing chemotherapy-induced neutropenia following treatment with plinabulin in combination with Neulasta.

The Food and Drug Administration approved Opdivo for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based chemotherapy.

In this episode of the “CURE Talks Cancer” podcast, we spoke with Drs. Ali Hendi and Jeremy Brauer about skin cancer awareness month.

The Food and Drug Administration approved Alunbrig for the first-line treatment of patients with ALK-positive metastatic non–small cell lung cancer.

Dr. Brian Rini discussed the benefits of treating patients with relapsed or refractory renal cell carcinoma with the vascular endothelial growth factor tyrosine kinase inhibitor.

The Food and Drug Administration approved the first new treatment option for Kaposi sarcoma in more than 20 years.

Researchers showed that integration of a comprehensive geriatric assessment with geriatrician-led management care improved quality of life for older adults with cancer.

Treatment with Lynparza in the maintenance setting extended overall survival by more than a year in women with platinum-sensitive relapsed ovarian cancer with BRCA1/2 mutations.

The Food and Drug Administration approved the first therapy to treat cancers with rearranged during transfection, or RET, gene alterations.

In this week’s episode of the “CURE Talks Cancer” podcast, we spoke with ESPN broadcaster Dick Vitale on his passion as a longtime champion to achieve victory over cancer.

In this episode of the “CURE Talks Cancer” podcast, an expert discusses the different types of skin cancer and how individuals can be proactive about screening.

The Food and Drug Administration approved Pemazyre for the treatment of patients with previously treated, advanced cholangiocarcinoma.

In this special edition of the “CURE Talks Cancer” podcast, we teamed up with our sister publication “OncLive on Air” to speak with a patient-doctor duo on myeloproliferative neoplasms.

The Food and Drug Administration approved the combination use of Braftovi plus Erbitux for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation.

The Food and Drug Administration approved the first and only erythroid maturation agent to treat patients with MDS who require red blood cell transfusions and have failed an erythropoiesis stimulating agent.

Patients with relapsed or refractory CD19-positive cancers experienced complete responses with no major side effects following treatment with CAR-NK cell therapy.

In this episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Angela Nicholas about her journey as a caregiver to her husband, who was diagnosed with colorectal cancer at 45, and why earlier screening is so vital.

Small cell lung cancer often becomes resistant to chemotherapy, and recent research highlights that these cells evolve, explaining why patients require further lines of treatment.

In this episode of the “CURE Talks Cancer” podcast, we spoke with Aki Smith, founder of Hope for Stomach Cancer, about her journey as her father’s caregiver and what she hopes the organization offers for others affected by a stomach cancer diagnosis.

Jeffrey Glen Jones – an American illustrator who started doing comic books about 25 years ago – is using his creative talents to illustrate the stories of those impacted by MPNs, as part of a campaign called Rare Reflections: MPNs Unmasked.

At the 37th Annual Miami Breast Cancer Conference, Dr. Valerie Lemaine discussed the signs and symptoms of BIA-ALCL, as well as how the disease is diagnosed and treated.

At CURE’s Educated Patient Breast Cancer Summit, Stephanie Seban shared the ways a patient can become their own best advocate to thrive through their breast cancer journey.

“A person becomes a survivor from the point they are diagnosed and for the balance of their lives,” Dr. Don S. Dizon said in a presentation at the 37th Annual Miami Breast Cancer Conference®.